<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ArticleSet PUBLIC "-//NLM//DTD PubMed 2.7//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/in/PubMed.dtd">
<ArticleSet>
<Article>
<Journal>
				<PublisherName>West Asia Organization for Cancer Prevention (WAOCP), APOCP's West Asia Chapter.</PublisherName>
				<JournalTitle>Asian Pacific Journal of Cancer Prevention</JournalTitle>
				<Issn>1513-7368</Issn>
				<Volume>14</Volume>
				<Issue>10</Issue>
				<PubDate PubStatus="epublish">
					<Year>2013</Year>
					<Month>10</Month>
					<Day>01</Day>
				</PubDate>
			</Journal>
<ArticleTitle>Prognostic Involvement of Nucleophosmin Mutations in Acute Myeloid Leaukemia</ArticleTitle>
<VernacularTitle></VernacularTitle>
			<FirstPage>5615</FirstPage>
			<LastPage>5620</LastPage>
			<ELocationID EIdType="pii">28182</ELocationID>
			
			
			<Language>EN</Language>
<AuthorList>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>1970</Year>
					<Month>01</Month>
					<Day>01</Day>
				</PubDate>
			</History>
		<Abstract>Nucleophosmin (NPM1) is a protein of highly conserved nature which works as a molecular chaperone and ismostly found in nucleoli. NPM also involved in the maturation of preribosomes and duplication of centrosomes.Furthermore, it is also active in control and regulation of the ARF-p53 tumor suppressor pathway. A high rateof incidence and prognostic involvement is reported by various authors in AML patients. In AML it behaves as afavorable prognostic marker. NPM mutations are more frequently associated with normal-karyotype AML andare usually absent in patients having abnormal or poor cytogenetic. NPM mutations are not frequent in otherhematopoietic tumors .Two main types of mutations have been described to date. Both of these cause abnormalcytoplasmic localization of NPM1. Their high incidence rate in normal karyoptype and their favorable naturem ake those mutations hot spot or front face mutations which should be checked before treatment starts.</Abstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">Nucleophosmin</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Prognostic marker</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">AML</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">normal karyotype</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">NPM mutations</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">exon 12</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://journal.waocp.org/article_28182_4e609baafedb7af682754d5602cf81dc.pdf</ArchiveCopySource>
</Article>
</ArticleSet>
